Almirall Registers a Net Profit of €14.4 Million Until September, 58.3% Less

Almirall’s profits plummet. The Catalan pharmaceutical company has reduced its net profit by 58.3% until the third quarter of 2023, with a figure of €14.4 million, compared to the €34.5 million registered in the same period of 2022, according to the accounts sent to the National Securities Markets Commission (Cnmv). 

However, the company has reported sales growth of 6.4% until September, with €674.6 million. The company has justified this figure by the good performance of key products in Europe, such as ilumetri, wynzora or klisyri, which have accumulated a growth rate of 15.9%.

On the other hand, Almirall has recorded a total EBITDA of €138.2 million until September of this year, 5.6% less than the value registered during the last year. The company added that this decline is “in line with expectations, reflecting the lower contribution of other income due to the AstraZeneca and Covis milestones, compared to the first nine months of 2022.”

If you want to find out more about Almirall and find the most important business news of the day, download for free our companion app Born2Invest.

Almirall has recorded a total EBITDA of €138.2 million until September, 5.6% less than in the same period of 2022

The gross margin of 64.9% has also been in line with expectations, reflecting the impact of the high cost of production goods and inflation that has affected the purchase of some materials. In addition, Almirall has reported that investment in its research and development (R&D) area was €78.9 million during the first nine months of 2023, reaching 11.6% of net sales.

Carlos Gallardo, president and CEO of Almirall, has assured that “the company has obtained solid operating results during the first nine months, and that is why we are pleased to revise upward our net sales estimates for the year.” The manager added that “we are prepared for the launch of lebrikizumab, a fact that will allow us to begin a transformative journey for our company.”

In fact, lebrikizumab received a positive opinion from the Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (EMA) for its marketing authorization in patients with moderate to severe atopic dermatitis. The Catalan company has the rights to distribute the solution in Europe, while Ely Lilly and Company has them reserved for the United States and the rest of the world.

__

(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.